Revelation Biosciences selects Avance Clinical as CRO for Titan Phase 2/3
Revelation Biosciences (REVB) selects Avance Clinical as CRO for its Phase 2/3 Titan study, which is expected to begin later this year.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Revelation Biosciences hires Avance Clinical as CRO for TITAN Phase 2/3
Revelation Biosciences (REVB) selects Avance Clinical as the CRO for its Phase 2/3 TITAN study.